Century Therapeutics, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Century Therapeutics completed an FDA pre-IND meeting for CNTY-813 (iPSC-derived islet replacement therapy for type 1 diabetes), achieving alignment on nonclinical data, Phase 1 manufacturing process, and clinical trial design. The company reported $197.2M in cash and investments as of June 30, 2026, providing runway into Q1 2029. CNTY-813 IND submission remains on track for 4Q 2026, with clinical data expected in H2 2027; CNTY-308 (CD19-targeted CAR-iT) is expected to enter clinic in 2026.
Why this rating
FDA alignment on lead program is meaningful validation reducing clinical risk. Cash position ($197.2M) covers ~2.75 years of operations against $212.5M market cap. IND submission near-term catalyst. No material partnership/financing changes; progressing on planned milestones.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.